Quick Facts

• Relief Target: May help address discomfort associated with acute, painful musculoskeletal conditions.
• Associated Use: Intended to support the management of rheumatic conditions, which may involve the joints, muscles, and skeleton.
• Symptom Support: May offer support for symptoms such as pain, inflammation, and restricted movement.

---

Tandrilax is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions. This therapeutic agent is intended to be used for short periods as part of a complete treatment plan that may also involve rest and physical therapy. Its use is designed to support the management of symptoms such as localized pain and inflammation that may accompany these conditions. Specific areas of use may include addressing discomfort related to lower back pain (lumbalgia), certain forms of arthritis like acute rheumatoid arthritis crises, and other inflammatory states affecting joints and muscles. The medication is used to modulate discomfort associated with rheumatic diseases, which are often characterized by pain and potential limitations in mobility. Before initiating treatment, patients should consult a healthcare professional to determine the most appropriate regimen for their condition.

Eligibility Map: Who can and cannot use Tandrilax

Regulatory agencies define the eligibility for Tandrilax (a combination of Diclofenac, Carisoprodol, Paracetamol, and Caffeine) through strict contraindications associated with its multiple active ingredients. Use is generally restricted to Adults without pre-existing high-risk conditions.

Eligibility Scope

Classification	Population/Condition
Use Allowed	Adults without contraindications.
Use Contraindicated	Children under 14 years old (except in specific cases of juvenile arthritis).
	Patients with known allergy or hypersensitivity to any component.
	Patients with Severe Cardiac, Hepatic (Liver), or Renal (Kidney) Failure.
	Patients with Active Peptic Ulcer Disease or Hemorrhagic Diatheses.
	Patients with Severe Hypertension or a history of Acute Intermittent Porphyria.
	Patients requiring pain relief for Coronary Artery Bypass Graft (CABG) surgery.
Restricted Use	Pregnancy: Contraindicated in the third trimester and not recommended otherwise.
	Lactation: Use is not recommended as ingredients are found in breast milk.
	Older Adults (Geriatric): Use requires caution due to increased risk of gastrointestinal adverse events.

Interactions with Other Medicines and Products

This section outlines officially documented interaction patterns for the active ingredients in Tandrilax (Diclofenac, Carisoprodol, Paracetamol, and Caffeine) as noted in government regulatory labeling (FDA, ANVISA, EMA-aligned cautions).

---

Contraindicated Combinations

Co-administration of Tandrilax is formally contraindicated with two major categories of products:

• Other Non-Steroidal Anti-inflammatory Drugs (NSAIDs): Use is prohibited because combining NSAIDs, such as Aspirin or Ibuprofen, significantly increases the documented risk of serious gastrointestinal events.
• Other Paracetamol-Containing Products: Concomitant use with any product containing Paracetamol (Acetaminophen) is prohibited due to the risk of exceeding the maximum safe daily limit, leading to toxicity.

---

Officially Documented Pharmacodynamic and Pharmacokinetic Interactions

Interacting Product Category	Regulatory Description of Interaction	Effect on Tandrilax or Co-administered Drug
CNS Depressants (e.g., sedatives, tranquilizers)	Documented additive effects	Increased CNS depression from Carisoprodol.
Anticoagulants/Antiplatelet Agents	Pharmacodynamic interaction	Increased risk of bleeding due to Diclofenac.
ACE Inhibitors / ARBs	Pharmacodynamic interaction	Diminished antihypertensive effect and increased risk of kidney problems.
Lithium, Methotrexate	Pharmacokinetic (Exposure)	Diclofenac may increase the plasma concentrations of these medicines.
Colestyramine	Pharmacokinetic (Absorption)	Reduces the absorption of Paracetamol if given within 1 hour.

---

Other Documented Product Interactions

• Alcohol (Ethanol): The regulatory label notes that alcohol increases the CNS side effects from Carisoprodol and heightens the documented risk of liver problems associated with Paracetamol.
• Population-Specific Caution: Patients with impaired kidney or liver function require caution, as the removal (clearance) of Carisoprodol and Paracetamol may be slower, potentially increasing their effects.

How Tandrilax Works: Pharmacodynamic Mechanism

This combination product modulates physiological responses across distinct biological systems. The primary peripheral action involves the non-selective inhibition of Cyclooxygenase ( COX) enzymes, mainly by Diclofenac. This molecular interaction curtails the Eicosanoid Synthesis Pathway, reducing the formation of Prostaglandins, which are chemical mediators that sensitize peripheral nociceptors and influence local vascular changes. This mechanism contributes to the modulation of the peripheral inflammation pathway.

Concurrently, the central component exerts its effect by acting as an allosteric modulator on GABAA receptors in the CNS (spinal cord and brainstem). This enhances inhibitory neurotransmission, leading to the interruption of the polysynaptic reflex arc that maintains involuntary muscle tone. Additionally, Paracetamol and Caffeine modulate central nociceptive signaling. Paracetamol elevates the nociceptive threshold through central COX and TRPV1/ CB1 receptor modulation. Caffeine acts as an Adenosine Receptor antagonist, resulting in a limitation of the central depressant effects from the muscle relaxant component and contributing to the central arousal component of the overall response profile.

Official Administration Guidelines for Tandrilax

Tandrilax is a fixed-dose combination drug that is administered according to standard labeling.

Feature	Standard Labeling Guidelines
Route of Administration	Oral Use (USO ORAL) only; supplied as a solid tablet.
Dosing Schedule	The standard regimen is one tablet, taken twice daily (every 12 hours). The maximum authorized dose is three tablets per 24 hours.
Intake Condition	The tablet should be taken with a meal to aid intake and mitigate potential irritation.
Course Duration	Use is limited to short-term therapy, generally not to exceed 10 days and should be the shortest possible duration.
Age Restriction	Restricted to Adult Use (USO ADULTO); safety and efficacy have not been established in patients under 14 years of age.

---

Administration Procedures

Frequency and Limits

The standard frequency of use is one tablet every 12 hours. In certain situations, the dose may be taken every 8 hours, but the total daily intake is not to surpass three tablets. The tablet contains a specific combination of Diclofenac, Carisoprodol, Paracetamol, and Caffeine and is intended to be taken as directed on the label.

Procedural Constraints

For proper administration, the tablet is to be swallowed whole with the aid of liquid and should not be crushed, broken, or chewed. If a dose is missed, it should be skipped if close to the next scheduled time, and the patient should resume the regular schedule without doubling the subsequent dose.

Tandrilax: Recent Clinical Evidence

This overview provides a structural summary of the clinical evidence available for the four-ingredient combination medication, focusing strictly on what was studied and the nature of the findings described in the research, without making any statements of efficacy, benefit, or clinical recommendation.

---

Evidence for Use in Acute Low Back Pain and Muscle Spasm

Research has primarily evaluated this combination in adult patients experiencing acute low back pain (lumbago) and lumboischialgia—conditions associated with acute or disruptive episodes. Clinical evaluation was conducted through short-term, randomized, double-blind, comparative clinical trials (RCTs). These studies examined patient-reported outcomes describing perceived discomfort, such as pain intensity measured by the Visual Analog Scale, and outcomes reflecting daily functioning or activity level. Findings were based on a comparison to another active muscle relaxant regimen, and the studies reported how symptoms evolved in the observed populations during the brief treatment period.

Study Design and Comparison Trials

Studies suggest the evidence landscape for the specific four-drug combination is derived from small-scale comparative trials that used a duration of approximately seven days. These studies are relevant in trials assessing short-term or episodic symptom patterns in acute musculoskeletal conditions. The research design focused on whether research examined the combination against the active comparator for outcomes related to physical discomfort. Research described patterns related to the measurements taken in the outcomes examined in the key comparative trial, noting that the data show patterns related to symptom measurements over the short period.

---

Long-Term Follow-up and Durability

Research so far indicates that the follow-up durations were limited, typically to only seven days. Because the study period was short, long-term effects are not fully established for the use of this specific fixed-dose combination. It is not yet clear whether the short-term symptom evolution observed during the study period continues or how symptom variability might be affected over a longer follow-up period. The absence of long-term data suggests the available findings reflect research exploring short-term symptom changes, but not chronic or persistent outcomes.

---

Evidence in Special Populations

The available studies primarily focused on a general cohort of adults presenting with recent, acute symptoms. Evidence is limited for certain groups, as specific studies have not been performed to evaluate the four-drug combination in older patients (aged 65 and over) or in pediatric patients (under 16 years of age). Similarly, research provides limited context regarding the use of the combination in populations relevant to pregnancy or breastfeeding, with data on these groups remaining insufficient or uncertain.

---

Research Limitations and Uncertainty

This section synthesizes the key evidence gaps. Studies contribute to the broader evidence landscape, but certainty remains low for several aspects. A major limitation is the lack of large-scale, dedicated placebo-controlled trials specifically designed to evaluate the efficacy of the four-drug combination as a whole. The comparative studies involved sample sizes were modest, which means that the findings describe group patterns but do not determine whether an individual will respond similarly. Furthermore, comparative evidence is lacking for many common treatment regimens, and the current evidence highlights what is known—and what is still uncertain—about the combination's performance in varied clinical scenarios.

Key Studies & References

1. A randomized, double-blind clinical trial, comparing the combination of caffeine, carisoprodol, sodium diclofenac and paracetamol versus cyclobenzaprine, to evaluate efficacy and safety in the treatment of patients with acute low back pain and lumboischialgia
2. NCT01421433: A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol

Common questions about Tandrilax (FAQ)

---

Q: How quickly can a person expect Tandrilax to start working?

Official information indicates that the onset of action is typically rapid. Relief is generally described as beginning within 30 minutes to one hour after the tablet is taken.

---

Q: How long does the effect of one dose of Tandrilax usually last?

The effects of the muscle relaxant component, Carisoprodol, are often described as lasting for approximately four to six hours. This duration helps inform the official dosing schedules, which often involve administration every 12 hours.

---

Q: What are the most common side effects of Tandrilax?

According to official product labeling, common side effects can include central nervous system effects such as drowsiness, dizziness, and headache. Gastrointestinal issues like stomach pain, nausea, vomiting, and diarrhea are also frequently noted due to the NSAID component.

---

Q: Does Tandrilax cause drowsiness or affect alertness?

Yes, official warnings confirm that Tandrilax can cause drowsiness and dizziness, which may impair mental and/or physical abilities. Official labels state that activities such as driving or operating machinery should be avoided until an individual knows how the medication will affect them.

---

Q: Can Tandrilax be used for chronic, long-term pain?

Official use is strictly defined as short-term therapy only. Regulatory documents generally limit the duration of use, often to a maximum of two to three weeks or less, due to potential safety risks associated with prolonged use.

---

Q: What is the difference in effect between Tandrilax and over-the-counter pain medicines?

Tandrilax is a prescription-only fixed-dose combination drug. Unlike most over-the-counter pain relievers, it combines an NSAID (Diclofenac) with a skeletal muscle relaxant (Carisoprodol) to target both pain/inflammation and involuntary muscle tension simultaneously.

---

Q: What is the difference in effect between Tandrilax and other combination pain relievers?

The product is characterized by its dual action, combining an NSAID (Diclofenac) with a skeletal muscle relaxant (Carisoprodol). This formulation is designed to provide relief by addressing both inflammation and involuntary muscle tension, a combination not typical in all pain relievers.

---

Q: Why is the use of Tandrilax sometimes limited to short-term treatment?

The short duration of use is specified in official labels to minimize safety risks. These risks include the potential for physical dependence linked to the muscle relaxant component and the documented gastrointestinal and cardiovascular risks of the NSAID component.

---

Q: Is dizziness a known side effect of Tandrilax?

Yes, regulatory documentation lists dizziness as a common side effect associated with the muscle relaxant component of the medication.

---

Q: Are there any serious side effects associated with Tandrilax that I should be aware of?

Official warnings highlight several serious risks. These include the potential for serious cardiovascular events (such as heart attack or stroke), severe gastrointestinal problems (including bleeding or ulceration), and the risk of physical dependence with prolonged use.

---

Q: Is there a risk of dependence or addiction with Tandrilax?

Yes, the Carisoprodol component of Tandrilax carries a warning regarding the risk of physical dependence, particularly if used for prolonged periods. The drug is classified as a controlled substance in some regions.

---

Q: Can Tandrilax cause stomach problems or ulcers?

Due to the NSAID component, Diclofenac, official warnings state there is an increased risk of serious gastrointestinal adverse events. These events include ulceration and bleeding in the stomach or intestines.

---

Q: Are there specific signs of an allergic reaction to Tandrilax to look out for?

Official documentation notes that immediate medical attention is necessary if an individual experiences signs of a severe allergic reaction. These signs may include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.

---

Q: Are there foods or drinks that should be avoided while taking Tandrilax?

Official documentation states that alcohol (ethanol) should be avoided because it can increase central nervous system side effects and heighten the risk of liver problems. Although no common foods are strictly prohibited, taking the tablet with a meal is an official administration condition.

---

Q: Can Tandrilax be used by people with high blood pressure or heart conditions?

Caution is advised for people with cardiovascular issues. The NSAID component increases the risk of serious cardiovascular events and may interact with blood pressure medications. The drug is formally contraindicated in patients with severe hypertension.

---

Q: Is Tandrilax safe for people with kidney or liver problems?

The drug is formally contraindicated in patients who have severe kidney or liver failure. Patients with any degree of existing kidney or liver impairment must use this medicine with caution, as official documents note drug clearance may be slower.

---

Q: Is there a concern about taking Tandrilax and driving or operating machinery?

Yes, due to the drug's potential to cause drowsiness and dizziness, official labels state that activities such as driving or operating machinery should be avoided. This caution remains in place until the individual is certain the medication does not impair their function.

---

Q: Does taking Tandrilax cause dry mouth?

Though not listed among the most frequently reported issues, dry mouth is mentioned in the official side effect profile of the Carisoprodol component.

---

Q: Is it normal to feel a little uncoordinated after taking this medication?

The muscle relaxant component affects the central nervous system. Official documentation lists loss of coordination as a potential symptom of an overdose, but it is not typically reported as a common side effect at prescribed dosages.

---

Q: Does Tandrilax have a sedative effect that could help with sleep?

The drug is known to cause drowsiness as a potential side effect due to the muscle relaxant. However, official regulatory documents state that this medicine is not indicated or recommended for the treatment of insomnia or as a sleep aid.

---

Q: Can Tandrilax be taken with common cold and flu medications?

Co-administration is formally prohibited if the cold or flu medication contains Paracetamol (Acetaminophen) or other NSAIDs. Combining these substances can significantly increase the risk of toxicity and serious adverse events.

---

Q: Has Tandrilax been studied for uses other than musculoskeletal pain?

Official indications and research evidence restrict the medicine's documented use to the treatment of acute musculoskeletal pain and associated muscle spasm. No other uses are officially listed or supported by the core regulatory documents.

---

Q: Is it necessary to take Tandrilax with food to avoid stomach upset?

Yes, regulatory documents state that the tablet should be taken with a meal. This administration condition is specified to help mitigate potential gastrointestinal irritation that can be caused by the NSAID component, Diclofenac.

---

Q: Can Tandrilax cause a person to feel unusually tired or weak?

The official common side effect of drowsiness is closely related to a feeling of tiredness. Furthermore, official labels note that the central nervous system depression caused by the muscle relaxant component may be perceived as general weakness or unusual tiredness.

---

Q: What information should I provide to a healthcare provider before starting Tandrilax?

Official documents describe the importance of disclosing a history of allergic reactions, pre-existing conditions like peptic ulcers, gastrointestinal bleeding, heart disease, kidney or liver disease, and the use of all other current medications, including over-the-counter pain relievers.

---

Q: Is the caffeine component necessary, and what is its role in the Tandrilax formulation?

Official descriptions of the drug's mechanism indicate that caffeine is included to act as a stimulant. Its primary function is to limit the central depressant effects that are caused by the muscle relaxant component, Carisoprodol.

---

Q: Can Tandrilax be used if I have a history of asthma or certain allergies?

Use is formally contraindicated if there is a known hypersensitivity or allergy to any of the ingredients. Official warnings also note that the NSAID component may potentially trigger asthma attacks in susceptible patients.

---

Q: Do clinical trials for Tandrilax include a diverse range of patient ages and health conditions?

Official research summaries note that studies primarily focused on a general cohort of adults presenting with acute symptoms. Evidence is described as limited for certain populations, such as older patients and those with concurrent complex health conditions.

How to Store and Dispose of Tandrilax?

This section outlines the official, label-based requirements for the storage and disposal of Tandrilax tablets.

---

Storage Requirements

Tandrilax must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with brief excursions permitted up to 30 C. It is mandatory to keep the tablets in the original container, which must be tightly closed, and to protect them from both moisture and heat. Storage is prohibited in hot, humid areas like a bathroom cabinet, as these conditions can reduce the medicine's potency.

Furthermore, the tablets must always be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired tablets should follow official guidelines. The preferred method is to utilize a drug take-back program or mail-back service. If this option is unavailable, the tablets must not be flushed down a toilet or drain. Instead, the medication should be mixed with an undesirable substance, placed in a sealed bag, and discarded in the household trash.